Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus serotype 26-expressing HPV16 vaccine
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
Adenovirus serotype 26-expressing HPV16 vaccine (Ad26.HPV16, JNJ-63682918) is a genetically engineered, replication-deficient adenoviral vector (Ad26) encoding the oncogenic human papillomavirus type 16 (HPV16) antigens E6 and E7. It is designed as a therapeutic cancer vaccine to induce immune responses against cells expressing these viral oncoproteins. The primary indication is for the treatment or prevention of diseases associated with persistent infection by high-risk HPV types, particularly cervical intraepithelial neoplasia and cervical cancer caused by HPV16. The drug is being developed using recombinant technology and delivered via intramuscular injection[1][2][4][5]. Janssen has led its development in partnership with Bavarian Nordic for some clinical programs[4][8].
- Other names
- adenovirus serotype 26-expressing HPV16 vaccineAd26 vector-based HPV16 vaccineAd-26 vector-based HPV16 vaccineAd 26 vector-based HPV16 vaccine
02
Targets
HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on adenovirus serotype 26-expressing HPV16 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus serotype 26-expressing HPV16 vaccine.